Content
09/12/2024
Sunnyvale, CA USA
Inflammatix
completed $57 million Series E Round funding. Investors include
Think.Health Ventures (lead), Khosla Ventures (lead), D1 Capital Partners, Iberis Capital, Northpond Ventures, OSF Ventures, RAW Ventures, Vesalius Ventures.
About
Inflammatix is developing an innovative point-of-care instrument platform to be used with a test to aid in the diagnosis of acute infection and sepsis by harnessing the immune system to deliver advanced immune response diagnostics. Our test rapidly informs the clinician about the likelihood of bacterial or viral infection and the need for ICU level care in the emergency department. Faster results may translate into more timely and appropriate therapy and level of care decisions.
*Products in development, are not for sale, and do not have marketing approval or clearance from regulatory authorities in any jurisdiction.
Startup
Sector:
MedTech
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
